Mylan Issues a Voluntary Recall for Epi Pen and Epi Pen Jr.

April 13, 2017

As of March 31, 2017, Mylan Pharmaceuticals has issued a voluntary recall for Epi Pen and Epi Pen Jr, epinephrine autoinjectors, from 13 specified lots.

FILE – In this July 8, 2016, file photo, a pharmacist holds a package of EpiPens epinephrine auto-injector, a Mylan product, in Sacramento, Calif. Mylan CEO Heather Bresch is defending the cost for life-saving EpiPens and is offering no suggestion that there are plans to lower prices. Bresch’s prepared testimony was released by the House Oversight and Government Reform Committee ahead of her Sept. 21 appearance before the panel. (AP Photo/Rich Pedroncelli, File)

The recall is due to a potential defective part that would result in the devices’ failure to activate. Although there have been a small number of defective devices reported, Mylan is taking proactive actions to ensure the safety of their products.

The recalled products were distributed between Dec. 17, 2015 and July 1, 2016. Please check your epinephrine autoinjectors and compare with the Mylan Site for lot numbers and steps to return and replace your defective epinephrine autoinjector.

For additional information please view the FDA’s official press release, here.